Efficacy and Safety of an Aclidinium Bromide Treatment for 12 Weeks or Longer in Patients with Moderate-To-Severe COPD: A Meta-Analysis.

CONCLUSIONS: Aclidinium reduced the incidence of exacerbation-related hospitalizations and improved quality of life, COPD symptoms and pulmonary function. In addition, aclidinium did not increase the incidence of non-fatal serious adverse events, cardiac adverse events, or COPD exacerbations and was not associated with increased mortality. PMID: 26846588 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26846588?dopt=Abstract

Source: COPD: Journal of Chronic Obstructive Pulmonary Disease - February 18, 2016 Category: Respiratory Medicine Tags: COPD Source Type: research